News
Important Only
European banks' NII growth to hit 4% in 2026, says Morgan Stanley
Morgan Stanley analysts see net interest income (NII) growth accelerating to 4% in 2026 for European banks after muted growth this year, driven by expanding margins and volume growthImprovement in PMIs point to an acceleration in loan growth, they say, while expecting loan growth to double to 4-5% y...Reuters
Mon, Nov 24
Nio Takes Critical Step for Its Next Growth Phase
Key PointsNio's recently launched sub-brands are driving deliveries significantly higher.Nio's recent move is to develop right-hand-drive vehicles for international expansion.The Chinese EV maker could slowly be making its way to the U.S. market.10 stocks we like better than Nio › Nio (NYSE: NIO) in...The Motley Fool
Mon, Nov 24
LIVE MARKETS-Morning bid: Holiday week could be prime time for yen intervention
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com.MORNING BID: HOLIDAY WEEK COULD BE PRIME TIME FOR YEN INTERVENTIONIt's been a slow start to the week in Asia with Japanese markets...Reuters
Mon, Nov 24
Is Centrus Energy Stock a Buy Now?
Key PointsCentrus is the only U.S. company with a license to produce HALEU. HALEU sales still represent only a small slice of total revenue. The stock has a rich valuation, with a forward P/E above 60. 10 stocks we like better than Centrus Energy › In line with a broader market sell-off, Centrus Ene...The Motley Fool
Mon, Nov 24
Stocks rise as traders ramp up bets of December Fed cut
SINGAPORE, Nov 24 (Reuters) - Global stocks began an event-filled week on the front foot on Monday, as investors took heart from growing expectations of a Federal Reserve rate cut in December even as policymakers remain divided over such a move.Reuters
Mon, Nov 24
Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine
[ Hong Kong, November 24th, 2025] Uni-Bio Science Group Limited (“Uni-Bio” or “the Group”) recently announced its official entry into a new phase of strategic development. Over the past few years, amidst profound biopharmaceutical industry transformation and multiple market challenges, the Group has consistently adhered to stable operations as its core focus, building financial resilience and commercialization capabilities. It has not only achieved sustained revenue growth and healthy cash flow, but also successfully advanced its blockbuster product – Bogutai® (Teriparatide Injection) – which was approved in China in January 2024, filling a crucial gap in its osteoporosis treatment portfolio. The Group is currently actively advancing the US FDA application for Uni-PTH, expected to be approved in 2027, and has entered a strategic collaboration with Kexing for six international markets, marking a key step in its global strategy.Building on these solid achievements, Uni-Bio has decided to shift its strategic focus comprehensively from "Stable Growth" to "Innovation-Driven." Leveraging next-generation synthetic biology and complex peptides as technological engines and focusing on the forefront of regenerative medicine, the Group is initiating a strategic leap from an "Excellent Pharmaceutical Company" to a "Global Leader in Regenerative Medicine."1. New Corporate Vision and Mission: Anchoring the Future of Regenerative MedicineAlongside this strategic upgrade, Uni-Bio announced its new corporate vision and mission, demonstrating not only its ambition to be rooted in China with a global outlook but also its deep consideration for the future of human health.Vision:" To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life."Mission:"Powering the Advancement of Regenerative Medicine with Next-Generation Synthetic Biology and Complex Peptide Innovation."2. Strategic Focus Areas: Comprehensive Breakthroughs in Four Regenerative Medicine FieldsCapitalizing on its profound expertise in synthetic biology and peptide technology, Uni-Bio is building a transformative pipeline covering four key areas – Muscular-Skeletal Regeneration, Skin Regeneration, Ocular Regeneration, and ENT (Ear, Nose, and Throat) Regeneration. These areas address core unmet clinical needs and promote the transition of regenerative medicine from the laboratory to broad clinical application through the deep integration of cutting-edge technologies.(1) Muscular-Skeletal RegenerationFocus on developing osteoporosis treatment and repair products, combined with stem cell technology, to drive breakthroughs in the diagnosis and treatment of bone, cartilage, and muscle injuries and degenerative diseases. Specific projects include:UB107 (BMP-2 Biomedical Material): A key growth factor in regenerative medicine, BMP-2 can be widely used clinically for bone defect reconstruction and spinal fusion surgery. It is expected to be approved for market launch in 2028, further consolidating Uni-Bio's market share and position in the field of bone regeneration. UB106 (Novel Target Antibody for Obesity): Addressing the limitations of current obesity treatments, UB106 directly targets issues such as muscle loss, frequent dosing, gastrointestinal side effects, and pancreatitis. It is expected to be approved as early as 2030, offering a new treatment option for patients with obesity.(2) Skin RegenerationLeveraging advanced growth factor technologies and innovative delivery systems to provide precise repair solutions for burns, scalds, and hard-to-heal wounds, while also offering comprehensive solutions in the medical aesthetics field. Recently approved products include:GeneTime® (Human Epidermal Growth Factor Derivative for External Use, Liquid, 30ml large specification): Approved by the NMPA in November 2025 (Approval No.: 國藥准字 S20258020). The approval of this new specification will significantly enhance GeneTime's clinical applicability and market coverage, meeting the diverse medication needs of medical institutions at all levels and the end market. Gene Queens® (Triple Protein Repair &Balance Ampoule): This product was approved recently, further completing the Group's comprehensive "Drug & Medical Device & Cosmetic" skincare solution portfolio.(3) Ocular RegenerationUni-Bio is actively exploring the field of ocular regeneration, utilizing advanced strategies such as hEGF and anti-VEGF, to remodel ocular surface and retinal function. Through active collaborations with leading international companies and top domestic universities, the Group is advancing the R&D of potential drugs for diseases, such as age-related macular degeneration. The Group’s mission is to accelerate the translation of cutting-edge technologies into clinical applications, thereby bringing new hope to patients with ocular diseases.(4) ENT RegenerationCentered on neurotrophic factor technology, Uni-Bio is pioneering innovative R&D in ENT regeneration, The Group is exploring novel solutions for reversing hearing loss and rebuilding olfactory function, driving new breakthroughs in the restoration of ENT organ function.3. Reiterating the Firm Commitment to Innovation and CollaborationEntering this new phase of strategic development, Uni-Bio is infusing the pioneering spirit of its startup days into a higher-level mission. This transformation marks the Group's official evolution from a biopharmaceutical company with strong commercialization capabilities to a clinical-value-oriented leader in regenerative medicine driven by frontier science.Consequently, Uni-Bio will more openly embrace collaboration across industry-academia-research-medicine, international technology partnerships, and co-building a capital ecosystem. It will actively seek deep synergies with top global research institutions, clinical experts, industry partners, and investors. To communicate this strategic vision and R&D progress more transparently and efficiently, Uni-Bio has simultaneously launched a new Chinese and English official website. The new website systematically presents the Company's pipeline across the four regenerative medicine fields, its technology platforms, and milestone achievements, while also strengthening investor relations (IR) and scientific collaboration access points, aiming to become a vital bridge connecting global partners.We sincerely invite partners, investors, research colleagues, and friends from all sectors interested in the future of regenerative medicine to visit Uni-Bio's new website, delve deeper into our scientific story, and join us in participating and witnessing this journey of reshaping life through innovation.Uni-Bio Chinese Website: https://www.uni-bioscience.com/Uni-Bio English Website: https://www.uni-bioscience.com/enEndAbout Uni-Bio Science：Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.24/11/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comView original content: EQS NewsEQS
Mon, Nov 24
Is XRP the Next Bitcoin?
Key PointsBitcoin has soared by 28,000% over the last 10 years.XRP is an emerging cryptocurrency disrupting the cross-border transactions market.10 stocks we like better than XRP › Over the last decade, the addition of crypto to portfolios has gained wider acceptance among investors.Perhaps the most...The Motley Fool
Mon, Nov 24
Crypto Daily｜Tom Lee Said Strategy Stock Has Become Key Risk Management Tool; Satoshi Nakamoto's Wealth Takes a 34% Hit as Bitcoin Plummets
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsTom Lee: Strategy Stock Has Become Key Risk Management ToolBitmine Chairman and CEO Tom Lee highlighted in an interview with CBDC that due to limited on-chain optio...Tiger News
Mon, Nov 24
MORNING BID EUROPE-Holiday week could be prime time for yen intervention
A look at the day ahead in European and global markets from Rae WeeIt's been a slow start to the week in Asia with Japanese markets closed for a holiday on Monday, but currency traders are watching with bated breath for any signs of official yen buying from Tokyo to stem its slide.The trading we...Reuters
Mon, Nov 24
INDIA STOCKS-Indian benchmark shares inch higher, led by IT on rising odds of US rate cut
By Bharath Rajeswaran Nov 24 (Reuters) - India's benchmark stock indexes inched higher on Monday, led by information technology shares on rising expectations of a Federal Reserve rate cut in December.The Nifty 50 .NSEI rose 0.19% to 26,118.05 and the BSE Sensex .BSESN was up 0.15% at 85,360.3...Reuters
Mon, Nov 24
BREAKINGVIEWS-China’s financial captain hits M&A hurdle
By Ka Sing Chan HONG KONG, Nov 24 (Reuters Breakingviews) - China’s financial captain is struggling to rally its troops. Beijing has tasked its sovereign fund, Central Huijin, with creating "two to three" world-leading investment banks by 2035. But a planned merger of three firms backed b...Reuters
Mon, Nov 24
Australia's Macmohan Holdings gains on new mining contract in Indonesia
Shares of Macmohan Holdings MAH.AX rise as much as 3.7% to A$0.555, their biggest intraday pct gain since November 17 Mining services provider says it has been awarded underground mining contract for Kucing Liar mine in Central Papua, Indonesia by Freeport-McMoRan's [RIC:RIC:FOGI.UL] unit Co sa...Reuters
Mon, Nov 24
India's HAL falls as Tejas jet crash weighs on sentiment
Shares of Hindustan Aeronautics HIAE.NS fall 3.4% to 4,440.10 rupees, set for their steepest decline since April 7, if losses hold HAL's Tejas fighter jet crashed during an aerial display at the Dubai Airshow on Friday and the Indian Air Force is setting up a court of inquiry to investigate the...Reuters
Mon, Nov 24
INDIA STOCKS-IT leads India's benchmark shares higher on rising odds of US rate cut
Nov 24 (Reuters) - India's benchmark stock indexes opened marginally higher on Monday, inching towards record highs, led by IT shares amid rising expectations of a rate cut by the Federal Reserve in December.The Nifty 50 .NSEI rose 0.21% to 26,122.8, while the BSE Sensex .BSESN was up 0.1% at 85...Reuters
Mon, Nov 24
24H | Chinese ADRs Jump as Investors Gear up for Alibaba Earnings, US Data
Chinese ADRs jumped in overnight trading ahead of a week packed with earnings reports and a deluge of US economic data delayed by the government shutdown.WeRide rose 5%; Hesai rose 4%; NetEase and Alibaba rose 3%; Baidu and NIO rose 2%; PDD Holdings Inc and Tencent Music rose 1%.Tiger News
Mon, Nov 24
Chinese chip stocks tumble on report US mulls easing Nvidia H200 export curbs
Shares of major Chinese chip makers slide to multi-month lows after a Reuters report that the United States is considering letting Nvidia NVDA.O sell H200 chips to ChinaChina AI chip maker Cambricon 688256.ss slides as much as 2.5% to a one-month low; down more than 10% month-to-dateThe CSI AI Index...Reuters
Mon, Nov 24
24H | Alibaba Jumps 4% as Qwen App Downloads Exceed 10 Million in First Week of Beta Testing
$Alibaba BABA)$ stock jumped 3.6% in overnight trading.Alibaba's AI assistant Qwen App has surpassed 10 million downloads in its first week of beta testing, outpacing ChatGPT, Sora, and DeepSeek to become the fastest-growing AI application in history.Tiger News
Mon, Nov 24
